According to a report in the American College of Rheumatology, Eli Lilly’s (LLY) peresolimab was superior to the placebo at week 12 for several key endpoints in patients with rheumatoid arthritis, but the drug’s efficacy was not differentiated from existing treatment options. “In context of observed efficacy combined with the number of reported malignancies and possible MACEs through week 60, the study was stopped based on the non-favorable benefit/risk profile for peresolimab in treating RA patients,” the journal states. Shares of AnaptysBio (ANAB), which is developing a similar PD-1 agonist, are down 4% to $19.39 in midday trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly (LLY) to Invest $5 Billion in New Virginia Plant as Pharma Tariffs Loom
- Eli Lilly to build $5B manufacturing facility in Virginia
- Eli Lilly (LLY) Falls as Novo Nordisk’s U.S. Survey Shows Its Drug Drowns ‘Food Noise’
- Novo Nordisk to seek U.S. approval for high-dose obesity shot, Bloomberg reports
- Eli Lilly price target lowered to $1,050 from $1,100 at JPMorgan